Technical Analysis for ARDX - Ardelyx, Inc.

Grade Last Price % Change Price Change
grade F 2.23 -3.88% -0.09
ARDX closed down 3.88 percent on Friday, January 18, 2019, on 51 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ARDX trend table...

Date Alert Name Type % Chg
Jan 18 180 Bearish Setup Bearish Swing Setup 0.00%
Jan 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 18 Outside Day Range Expansion 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.88%
Jan 17 Inside Day Range Contraction -3.88%
Jan 17 Wide Bands Range Expansion -3.88%
Jan 16 180 Bearish Setup Bearish Swing Setup 0.00%
Jan 16 Outside Day Range Expansion 0.00%
Jan 16 Wide Bands Range Expansion 0.00%

Older signals for ARDX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Ardelyx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics to treat cardio-renal, gastrointestinal (GI), and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal, GI, and metabolic diseases. Ardelyx, Inc. has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Is ARDX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.1
52 Week Low 1.6
Average Volume 355,741
200-Day Moving Average 3.7945
50-Day Moving Average 2.4134
20-Day Moving Average 2.0605
10-Day Moving Average 2.321
Average True Range 0.1917
ADX 24.23
+DI 18.5466
-DI 15.627
Chandelier Exit (Long, 3 ATRs ) 1.9349
Chandelier Exit (Short, 3 ATRs ) 2.1751
Upper Bollinger Band 2.6215
Lower Bollinger Band 1.4995
Percent B (%b) 0.65
BandWidth 54.452803
MACD Line -0.0037
MACD Signal Line -0.0566
MACD Histogram 0.0529
Fundamentals Value
Market Cap 105.8 Million
Num Shares 47.4 Million
EPS -2.44
Price-to-Earnings (P/E) Ratio -0.91
Price-to-Sales 0.00
Price-to-Book 1.59
PEG Ratio -0.07
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.52
Resistance 3 (R3) 2.53 2.46 2.47
Resistance 2 (R2) 2.46 2.38 2.45 2.45
Resistance 1 (R1) 2.34 2.34 2.31 2.33 2.44
Pivot Point 2.27 2.27 2.25 2.26 2.27
Support 1 (S1) 2.15 2.19 2.12 2.14 2.02
Support 2 (S2) 2.08 2.15 2.07 2.01
Support 3 (S3) 1.96 2.08 1.99
Support 4 (S4) 1.95